We are live on
!
Find out more
CLC
Charles-Lim Capital Portfolio holdings
AUM
$319M
1-Year Est. Return
13.77%
This Fund
S&P 500
This Quarter
Est. Return
+33.32%
1 Year Est. Return
-13.77%
3 Year Est. Return
+4.44%
5 Year Est. Return
-59.29%
10 Year Est. Return
+482.41%
AUM
$571M
AUM Growth
+$85.4M
(+18%)
Cap. Flow
-$53.6M
Cap. Flow
% of AUM
-9.39%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
2
Closed
1
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICICI Bank
IBN
|
+$34.8M |
| 2 |
HDFC Bank
HDB
|
+$13.9M |
| 3 |
Dr. Reddy's Laboratories
RDY
|
+$4.96M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 72.77% |
| 2 | Financials | 27.23% |
| 3 | Healthcare | 0% |
Similar funds
TPW
SFS
WI
BFS
BPFA
CWA
SC
BMCM
Charles-Lim Capital's Q2 2019 Portfolio in Review
As of Q2 2019, Charles-Lim Capital held 4 positions worth $571M, up 18% from $485M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Charles-Lim Capital withdrew a net $53.6M in Q2 2019, closing 1 position and reducing 2 holdings. Its most notable exit was Dr. Reddy's Laboratories, an estimated $4.96M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 73% of assets, up from 61% a quarter earlier, followed by Financials and Healthcare.
- Charles-Lim Capital's biggest Q2 2019 reduction was ICICI Bank, cutting an estimated $34.8M.
- Charles-Lim Capital fully exited Dr. Reddy's Laboratories in Q2 2019, selling an estimated $4.96M.
- Charles-Lim Capital's ten largest holdings make up 100% of its $571M portfolio in Q2 2019.
- Charles-Lim Capital opened 0 new positions and closed 1 in Q2 2019.
- Charles-Lim Capital's portfolio value rose 18% quarter-over-quarter to $571M.
Based on Charles-Lim Capital's 13F filing for Q2 2019, filed 14 Aug 2019.